FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386152079> ?p ?o ?g. }

• W4386152079 abstract "Patients with relapsed/refractory multiple myeloma (RRMM) have a high unmet treatment need. Belantamab mafodotin (belamaf), a first-in-class, B-cell maturation antigen-binding antibody-drug conjugate, eliminates myeloma cells through direct cell killing and an anti-myeloma immune response.DREAMM-2 (NCT03525678) was a phase 2, two-arm, open-label trial in patients with heavily pretreated RRMM who had three or more prior therapies, were refractory to an immunomodulatory agent and a proteasome inhibitor, and refractory or intolerant to an anti-CD38 monoclonal antibody. Belamaf was given at 2.5 or 3.4 mg/kg every 3 weeks. The primary end point was overall response rate (ORR); secondary end points included progression-free survival (PFS), overall survival (OS), safety, ocular symptoms, and health-related quality of life (HRQOL).This final analysis (cutoff date, March 31, 2022), N = 223, with median follow-up of 12.5 and 13.8 months, demonstrated an ORR of 32% and 35%, median PFS of 2.8 and 3.9 months, and median OS of 15.3 and 14.0 months in the 2.5 mg/kg and 3.4 mg/kg cohorts, respectively. Median duration of response was 12.5 and 6.2 months. No new safety signals were observed; the most common Grade 3 and 4 adverse events were keratopathy (29% vs. 25%), thrombocytopenia (22% vs. 29%), and anemia (21% vs. 28%). HRQOL outcomes suggest that overall global health status/quality of life, physical and role functioning, and overall disease symptoms were maintained or improved during treatment.This final analysis of DREAMM-2 confirms that in patients with triple-class refractory RRMM, single-agent belamaf results in durable and clinically meaningful responses with a manageable safety profile." @default.
• W4386152079 created "2023-08-26" @default.
• W4386152079 creator A5001577825 @default.
• W4386152079 creator A5006108161 @default.
• W4386152079 creator A5016074876 @default.
• W4386152079 creator A5018048721 @default.
• W4386152079 creator A5022520524 @default.
• W4386152079 creator A5023276777 @default.
• W4386152079 creator A5023624767 @default.
• W4386152079 creator A5024291639 @default.
• W4386152079 creator A5028905515 @default.
• W4386152079 creator A5030746256 @default.
• W4386152079 creator A5042432109 @default.
• W4386152079 creator A5043387663 @default.
• W4386152079 creator A5043526996 @default.
• W4386152079 creator A5048362577 @default.
• W4386152079 creator A5052787074 @default.
• W4386152079 creator A5053731124 @default.
• W4386152079 creator A5064710410 @default.
• W4386152079 creator A5065834452 @default.
• W4386152079 creator A5076625662 @default.
• W4386152079 creator A5082564837 @default.
• W4386152079 creator A5082712392 @default.
• W4386152079 creator A5084492085 @default.
• W4386152079 creator A5087935452 @default.
• W4386152079 creator A5091215609 @default.
• W4386152079 date "2023-08-25" @default.
• W4386152079 modified "2023-09-30" @default.
• W4386152079 title "Single‐agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM‐2 trial" @default.
• W4386152079 cites W2202939373 @default.
• W4386152079 cites W2945759817 @default.
• W4386152079 cites W2969931905 @default.
• W4386152079 cites W2979807505 @default.
• W4386152079 cites W3133229959 @default.
• W4386152079 cites W3160195538 @default.
• W4386152079 cites W3183441818 @default.
• W4386152079 cites W4211058750 @default.
• W4386152079 cites W4281631369 @default.
• W4386152079 cites W4281914911 @default.
• W4386152079 cites W4281965930 @default.
• W4386152079 cites W4282033105 @default.
• W4386152079 cites W4282580226 @default.
• W4386152079 cites W4283328585 @default.
• W4386152079 cites W4286298719 @default.
• W4386152079 cites W4293116214 @default.
• W4386152079 cites W4295424675 @default.
• W4386152079 cites W4303419031 @default.
• W4386152079 cites W4309215158 @default.
• W4386152079 cites W4323848852 @default.
• W4386152079 cites W4379330610 @default.
• W4386152079 doi "https://doi.org/10.1002/cncr.34987" @default.
• W4386152079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37622738" @default.
• W4386152079 hasPublicationYear "2023" @default.
• W4386152079 type Work @default.
• W4386152079 citedByCount "2" @default.
• W4386152079 countsByYear W43861520792023 @default.
• W4386152079 crossrefType "journal-article" @default.
• W4386152079 hasAuthorship W4386152079A5001577825 @default.
• W4386152079 hasAuthorship W4386152079A5006108161 @default.
• W4386152079 hasAuthorship W4386152079A5016074876 @default.
• W4386152079 hasAuthorship W4386152079A5018048721 @default.
• W4386152079 hasAuthorship W4386152079A5022520524 @default.
• W4386152079 hasAuthorship W4386152079A5023276777 @default.
• W4386152079 hasAuthorship W4386152079A5023624767 @default.
• W4386152079 hasAuthorship W4386152079A5024291639 @default.
• W4386152079 hasAuthorship W4386152079A5028905515 @default.
• W4386152079 hasAuthorship W4386152079A5030746256 @default.
• W4386152079 hasAuthorship W4386152079A5042432109 @default.
• W4386152079 hasAuthorship W4386152079A5043387663 @default.
• W4386152079 hasAuthorship W4386152079A5043526996 @default.
• W4386152079 hasAuthorship W4386152079A5048362577 @default.
• W4386152079 hasAuthorship W4386152079A5052787074 @default.
• W4386152079 hasAuthorship W4386152079A5053731124 @default.
• W4386152079 hasAuthorship W4386152079A5064710410 @default.
• W4386152079 hasAuthorship W4386152079A5065834452 @default.
• W4386152079 hasAuthorship W4386152079A5076625662 @default.
• W4386152079 hasAuthorship W4386152079A5082564837 @default.
• W4386152079 hasAuthorship W4386152079A5082712392 @default.
• W4386152079 hasAuthorship W4386152079A5084492085 @default.
• W4386152079 hasAuthorship W4386152079A5087935452 @default.
• W4386152079 hasAuthorship W4386152079A5091215609 @default.
• W4386152079 hasBestOaLocation W43861520791 @default.
• W4386152079 hasConcept C121332964 @default.
• W4386152079 hasConcept C126322002 @default.
• W4386152079 hasConcept C141071460 @default.
• W4386152079 hasConcept C142424586 @default.
• W4386152079 hasConcept C159110408 @default.
• W4386152079 hasConcept C197934379 @default.
• W4386152079 hasConcept C203092338 @default.
• W4386152079 hasConcept C2776364478 @default.
• W4386152079 hasConcept C2778248108 @default.
• W4386152079 hasConcept C2779951463 @default.
• W4386152079 hasConcept C535046627 @default.
• W4386152079 hasConcept C71924100 @default.
• W4386152079 hasConcept C87355193 @default.
• W4386152079 hasConcept C90924648 @default.
• W4386152079 hasConceptScore W4386152079C121332964 @default.
• W4386152079 hasConceptScore W4386152079C126322002 @default.
• W4386152079 hasConceptScore W4386152079C141071460 @default.
• W4386152079 hasConceptScore W4386152079C142424586 @default.

• next